Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

All studies

Lenvatinib (off Label)

ACC-LEN14

Eisai (investigator studies) · Phase 2 · Completed · Enrollment 26

NCT02860936

ArmPopulationDoseEstimandComparatorEfficacy
Lenvatinib 24 mgR/M salivary ACC (n = 26 evaluable)24 mgSingle armn/robjective response rate: 11.5%, primary analysismedian progression-free survival: 9.1 months, primary analysismedian overall survival: 27 months, primary analysis